Investigate / DD
Understand DuPont de Nemours, Inc.
After divesting or separating several businesses, can the two remaining segments sustain the company's performance on their own?
Snapshot reviewed 2026-10-02. Source published 2026-08-04. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Ownership-page coverage is not available for this company. That does not mean no tracked investor owns it.
Your research workspace / DD
Ask better questions. Keep the evidence.
Explore the available sources for DuPont de Nemours, Inc., then keep what deserves another look.
01 Investor activity
Ownership coverage is unavailable—not zero owners.
02 Business evidence
Reported evidence
What does the company do?
DuPont provides advanced solutions across healthcare, water, construction and industrial markets, helping customers advance technology pipelines and address specific challenges.
Latticework interpretation
What could support the case?
If medical packaging and water-filtration offerings attract demand in their stated end markets, they could support DuPont’s remaining Healthcare & Water Technologies business.
Latticework interpretation
What could break the case?
If the Qnity Distribution and related transactions failed to qualify for tax-free treatment, DuPont could incur significant tax liabilities with a possible material adverse impact on its business.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
DuPont provides advanced solutions across healthcare, water, construction and industrial markets, helping customers advance technology pipelines and address specific challenges.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $1,819m | $1,749m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $143m | $59m |
Comparison caveat: Revenue covers continuing operations, while net income includes discontinued businesses and disposal effects. The Qnity separation and Aramids sale mean headline profit is not only the two remaining segments.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If medical packaging and water-filtration offerings attract demand in their stated end markets, they could support DuPont’s remaining Healthcare & Water Technologies business.
Supporting filing ↗The strongest caution
If the Qnity Distribution and related transactions failed to qualify for tax-free treatment, DuPont could incur significant tax liabilities with a possible material adverse impact on its business.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How does the remaining portfolio differ in market exposure?
Starting evidence: Diversified Industrials covers building technologies and industrial technologies serving construction, aerospace, automotive and printing and packaging markets, which may behave differently from healthcare and water markets.
Investigate next: Review segment-level disclosures for end-market exposure and how each segment's results have moved across recent periods.
Read the supporting filing ↗How might tax-related separation risks affect the company?
Starting evidence: The Tax Matters Agreement may allocate responsibility for certain taxes between DuPont and Qnity, so outcomes could depend on how liability is assigned.
Investigate next: Read the tax matters agreement terms and any accrued liabilities or contingencies disclosed in the notes.
Read the supporting filing ↗How will proceeds and the Arclin consideration be used?
Starting evidence: The Aramids sale included cash, a note receivable and a non-controlling equity interest, so value realized may depend on those non-cash components.
Investigate next: Check cash flow and capital allocation disclosures for how proceeds were used and how the note and equity interest are accounted for.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.